TITLE

Incorporating Drug-Resistance Measurements into the Clinical Management of HIV-1 Infection

AUTHOR(S)
Zolopa, Andrew R.
PUB. DATE
September 2006
SOURCE
Journal of Infectious Diseases;9/16/2006, Vol. 194, pS59
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Testing for resistance to antiretrovirals is considered to be standard of care and is widely used in the management of human immunodeficiency virus (HIV)-infected persons. Despite the widespread use of resistance testing, the clinician still faces a number of challenges when applying these technologies in the optimal management of antiretroviral therapy. Both genotype and phenotype tests require interpretation, and available interpretative algorithms for genotypes and resistance cutoffs for phenotypes are incomplete and evolving. Even experts in HIV resistance do not completely agree in their interpretation of genotypes. Moreover, discordant results between genotypes and phenotypes are a common source of confusion when both tests are used to evaluate resistance in a patient. Finally, newer indicators, such as replication capacity, are clinically available and appear to have prognostic value, but how this in vitro measure should be used in the management of antiretroviral therapy remains to be fully defined.
ACCESSION #
22316931

 

Related Articles

  • Methods to Assess Population Effectiveness of Therapies in Human Immunodeficiency Virus Incident and Prevalent Cohorts. Tarwater, Patrick M.; Mellors, John; Gore, Mary E.; Margolick, Joseph B.; Phair, John; Detels, Roger; Muñoz, Alvaro // American Journal of Epidemiology;Oct2001, Vol. 154 Issue 7, p675 

    Two methods are presented for measuring population effectiveness (i.e., reduction of disease in a population in which only some receive treatment) of antiretroviral therapy among human immunodeficiency virus (HIV)-infected men at risk for acquired immunodeficiency syndrome (AIDS) and followed...

  • HIV-1 Load Quantitation: A 17-Year Perspective. Holodniy, Mark // Journal of Infectious Diseases;9/16/2006, Vol. 194, pS38 

    During the past decade and a half, quantitation of plasma-associated human immunodeficiency virus type 1 (HIV-1) RNA level, or HIV-1 load, has been validated in clinical practice and clinical trials as an important surrogate marker of HIV-1 disease progression and of the potency and durability...

  • Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1–Infected Patients: A Randomized Open-Label Trial. de Castro, Nathalie; Braun, Joséphine; Charreau, Isabelle; Pialoux, Gilles; Cotte, Laurent; Katlama, Christine; Raffi, François; Weiss, Laurence; Meynard, Jean-Luc; Yazdanpanah, Yazdan; Delaugerre, Constance; Madelaine-Chambrin, Isabelle; Aboulker, Jean-Pierre; Molina, Jean-Michel // Clinical Infectious Diseases;10/15/2009, Vol. 49 Issue 8, p1259 

    Background. Among patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection, salvage regimens including enfuvirtide have demonstrated sustained efficacy. Because of reluctance to use subcutaneous injections, raltegravir may be an alternative to replace enfuvirtide...

  • UTILISATION OF THE NATIONAL ANTIRETROVIRAL THERAPY GUIDELINES AMONG HEALTH CARE PROFESSIONALS WORKING IN ABUJA TREATMENT CENTRES, NIGERIA. Zungu, Lindiwe I.; Abu, Ugbede O.; Ogunbanjo, Gboyega A.; Setswe, Geoffrey K. // African Journal of Primary Health Care & Family Medicine;2009, Vol. 1 Issue 1, p88 

    Background: Access to and utilisations of the National Antiretroviral Treatment Guidelines (NATG) are valuable factors for effective programme implementation. The objective of this study was to investigate the accessibility of the NATG and their utilisation by health care professionals from five...

  • HIV/AIDS: Recent Advances in Antiretroviral Agents. Nikolopoulos, Georgios; Bonovas, Stefanos; Tsantes, Argirios; Sitaras, Nikolaos M. // Mini Reviews in Medicinal Chemistry;Jul2009, Vol. 9 Issue 8, p900 

    Despite the considerable progress in antiretroviral therapy, the eradication of HIV-1 remains unfeasible. Therefore, novel agents are under investigation. The aim of this review is to summarize the conventional compounds, to describe the recently approved agents, and to take a comprehensive look...

  • Tipranavir. Flexner, Charles; Bate, Guy; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Dec2005, Vol. 4 Issue 12, p955 

    The article focuses on the discovery of Tipranavir, a drug used in the treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents. The development of antiretroviral regimens in which inhibitors of the HIV-1 protease are combined with nucleoside...

  • Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: A combined study of two cohorts. Cysique, Lucette A.; Maruff, Paul; Brew, Bruce J. // Journal of NeuroVirology;Dec2004, Vol. 10 Issue 6, p350 

    The objective of this study was to assess the prevalence and pattern of neuropsychological impairment in cohorts of human immunodeficiency virus (HIV)-infected individuals across pre- and post-HAART (highly active antiretroviral therapy) eras. Two cohorts of HIV-infected individuals attending...

  • tipranavir.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1152 

    This article presents a nurse's guide to the antiretroviral agent tipranavir. Tipranavir is indicated for advanced HIV disease resistant to other anti-HIV therapies. Tipranavir works by inhibiting the processing of viral polyproteins, preventing formation of mature virions. Its therapeutic...

  • Combined therapy provides better control of HIV. Zablocki, Elaine // Managed Healthcare Executive;Aug2004, Vol. 14 Issue 8, p50 

    Focuses on the treatment of human immunodeficiency virus infection that relies on a combination of medications known as highly active antiretroviral therapy. Identification of the available classes of drugs; Coverage of all retroviral products in various health plans; Prevention of viral entry...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics